Ligand to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) announced the participation of its CEO, Todd Davis, and CFO, Tavo Espinoza, in two upcoming investor conferences. The company will attend the Craig-Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, where management will hold one-on-one meetings with investors. Additionally, Ligand will present at the Goldman Sachs Global Healthcare Conference in Miami on June 12, 2024, at 4:00 p.m. ET, and will also be available for one-on-one meetings. Interested investors should contact their respective institutional equity sales representatives at Craig-Hallum or Goldman Sachs.

Positive

• Ligand Pharmaceuticals' executives will engage directly with investors, potentially increasing investor confidence.
• Participation in the Craig-Hallum and Goldman Sachs conferences could enhance Ligand's visibility within the investor community.
• One-on-one meetings provide an opportunity for personalized investor relations, which can positively impact stock perception.

Negative

• The press release lacks specific new financial or business updates, offering immediate information for investors.
• The announcement does not include any groundbreaking news or developments that might significantly impact the stock price short-term.

JUPITER, Fla.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:

• Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 29, 2024.

• Goldman Sachs Global Healthcare Conference (Miami). Management will present on June 12, 2024 at 4:00 p.m. ET.

Management is scheduled to host one-on-one meetings with investors and attendees during both of these conferences. Investors interested in arranging one-on-one meetings should contact their Craig-Hallum and / or Goldman Sachs institutional equity sales representative.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523216667/en/

For Ligand:

Investors:

Michael Jeong

investors@ligand.com

(561) 214-4232

LifeSci Advisors

Bob Yedid

bob@lifesciadvisors.com

(516) 428-8577

Media:

Kellie Walsh

media@ligand.com

(914) 315-6072

Source: Ligand Pharmaceuticals Incorporated

FAQ

When and where will Ligand Pharmaceuticals participate in upcoming investor conferences?

Ligand Pharmaceuticals will attend the Craig-Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, and the Goldman Sachs Global Healthcare Conference in Miami on June 12, 2024.

Who from Ligand Pharmaceuticals will be attending the investor conferences?

The CEO, Todd Davis, and the CFO, Tavo Espinoza, will represent Ligand Pharmaceuticals at the upcoming investor conferences.

What will Ligand Pharmaceuticals present at the Goldman Sachs Global Healthcare Conference?

Ligand Pharmaceuticals management will present at the Goldman Sachs Global Healthcare Conference on June 12, 2024, at 4:00 p.m. ET.

How can investors arrange one-on-one meetings with Ligand Pharmaceuticals' management during the conferences?

Investors interested in arranging one-on-one meetings should contact their Craig-Hallum or Goldman Sachs institutional equity sales representatives.

What is the stock symbol for Ligand Pharmaceuticals?

The stock symbol for Ligand Pharmaceuticals is LGND.